Tenascin-C expression relates to clinicopathological features in pilocytic and diffuse astrocytomas.
OBJECTIVE
Tenascin-C (TN-C) is an extracellular matrix brain glycoprotein for which conflicting in vitro and in vivo results are reported in the literature dealing with its involvement in astrocytoma aggressiveness, in particular astrocytoma invasion. In view of these conflicting results and the lack of data available on low-grade astrocytomas, the present study focuses on pilocytic World Health Organization (WHO) grade I, and diffuse WHO grade II astrocytomas, that is, two histological entities associated with very different invasive abilities.


METHODS
Using real-time reverse transcription polymerase chain reaction and immunohistochemistry, we analysed the TN-C expression in normal brain tissue as well as in a series of 54 pilocytic and 53 grade II astrocytomas.


CONCLUSIONS
Our data on normal brain showed that while TN-C is largely expressed in supratentorial white matter, it was largely absent in infratentorial white matter. Paralleling these observations, we showed that TN-C expression in low-grade astrocytomas similarly varies according to tumour site. Cox regression analysis evidenced that TN-C provided an independent prognostic value which is enhanced in the case of grade II astrocytomas for which positive TN-C expression is associated with a higher risk of recurrence. We also analysed TN-C expression specifically in vascular areas of low-grade astrocytomas without demonstrating any prognostic value for this additional feature.


RESULTS
Similarly to normal brain, low-grade astrocytomas exhibit variations in TN-C expression with site, and this expression is associated with an independent prognostic value in terms of recurrence.
Maris
C
C
Department of Pathology, Erasme University Hospital, Université Libre de Bruxelles, Brussels, Belgium.
Rorive
S
S
Sandras
F
F
D'Haene
N
N
Sadeghi
N
N
Bièche
I
I
Vidaud
M
M
Decaestecker
C
C
Salmon
I
I
D000328:Adult; D000367:Age Factors; D001254:Astrocytoma / Q000378:metabolism* / Q000401:mortality / Q000473:pathology*; D014408:Biomarkers, Tumor / Q000032:analysis; D001932:Brain Neoplasms / Q000378:metabolism* / Q000401:mortality / Q000473:pathology*; D002648:Child; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D053208:Kaplan-Meier Estimate; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000473:pathology; D011379:Prognosis; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013120:Spinal Cord Neoplasms / Q000378:metabolism / Q000401:mortality / Q000473:pathology; D019063:Tenascin / Q000096:biosynthesis*
D014408:Biomarkers, Tumor; D019063:Tenascin